{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0326","statisticalMethod":"Quantile regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.99","upperLimit":"2.00","value":"1.15"},{"groupId":"OG001","lowerLimit":"0.95","upperLimit":"2.10","value":"1.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"TTR was defined as the time from the index date to the first documentation of OR. OR is defined as having a best overall response (BOR) of confirmed sCR, CR, VGPR or PR per IMWG criteria. Analysis was performed using IPTW method to balance participant characteristics among reporting groups.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants with TCR MM who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) were included.","id":"OG000","title":"Study C1071003 Cohort A"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from Flatiron Health database were included.","id":"OG001","title":"Flatiron Health Cohort"}],"paramType":"MEDIAN","populationDescription":"Eligible participants from study C1071003 (Cohort A) and RW participants identified from COTA and Flatiron Health databases were included. Here, \"Overall Number of Participants Analyzed\" is the number of participants after application of IPTW method to raw numbers.","reportingStatus":"POSTED","timeFrame":"From index date to date of first documentation of OR (median follow-up of 10.4 months for study C1071003 cohort A, 8.8 months and 7.7 months for COTA and Flatiron Health cohorts)","title":"Time to Response-Comparison Between Elranatamab in Study C1071003 Cohort A and Flatiron Health Cohort Using IPTW Analysis","type":"SECONDARY","unitOfMeasure":"Months"}